Dyne Therapeutics, Inc. (DYN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Dyne Therapeutics, Inc. (DYN)
Company Performance

Current Price

as of Oct 16, 2024

$35.40

P/E Ratio

N/A

Market Cap

$3.55B

Description

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerDYN
  • Price$35.4+5.39%

Trading Information

  • Market Cap$3.55B
  • Float75.00%
  • Average Daily Volume (1m)1,087,482
  • Average Daily Volume (3m)1,242,125
  • EPS-$3.58

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$65.10M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$71.56M
  • EV$2.51B
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B4.57
Documents